drugset / Trial / NCT00840099

600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions

NCT00840099

Phase 1 Completed 48 enrolled Teva Pharmaceuticals USA
Non-randomizedCrossoverOpen-labelOther

Summary

The objective of this study is to assess the bioequivalence between Amoxicillin and Clavulanate Potassium for Oral Suspension, 600/42.9 mg/5 mL and Augmentin ES-600™ for Oral Suspension, 600/42.9 mg/5 mL in healthy, male and female subjects, under fasting conditions.

Timeline

Start
2002-08
Primary completion
2002-08
Completion
2002-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 600 mg Oral
Subject Clavulanate Unknown 42.9 mg Oral

Indications

No indication recorded.